DAWN

Day One Biopharmaceuticals, Inc. [DAWN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

DAWN Stock Summary

Top 10 Correlated Stocks

DAWN

In the News

DAWN Financial details

Company Rating
-
Market Cap
1.2B
Income
-181.9M
Revenue
560K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
155
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-7.68
Forward P/E
-
PEG
-6.46
P/S
-
P/B
-3.08
P/C
-
P/FCF
-8.76
Quick Ratio
16.57
Current Ratio
16.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
17.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.81%
-
-
-
-
SMA20
-10.22%
SMA50
18.44%
SMA100
25%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-1546%
ROC
-0.49%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.67-17.85
52W High
-50.79%
52W Low
-7.06%
RSI
48.3
Rel Volume
1.44
Avg Volume
636.27K
Volume
919.2K
Perf Week
0.66%
Perf Month
18.82%
Perf Quarter
29.09%
Perf Half Y
23.93%
-
-
-
-
Beta
-1.481
-
-
Volatility
0.21%, 0.77%
Prev Close
-0.65%
Price
8.365
Change
-1.59%

Something similar

Top by Market Cap
VTI
LLY.DE
GOOGL
NVD.DE
TSLA
Same Sector
0503.HK
PDEX
OGEN
0UNL.L
0RD1.L
Top Correlated Stocks
SEDG
0L7S.L
SFB
1925.T
DWAHY
Similar Market Cap
IQDG
LSAQ
0RP4.L
GIII
WINA

Company Profile

Healthcare Biotechnology
  • Volume Average 636.27K
  • Market Capitalization 1.2B
  • Employee 155
  • CEO Dr. Jeremy Bender M.B.A., Ph.D.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2021-05-27
  • Website https://dayonebio.com

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.